Which insulin is the best?

There is no single “best” insulin for all individuals—insulin selection must be individualized based on a person’s diabetes type, glycemic targets, lifestyle, daily routine, risk of hypoglycemia, renal or hepatic function, comorbidities, and personal preferences. Insulins are broadly categorized by onset, peak, and duration of action: rapid-acting (e.g., insulin aspart, lispro, glulisine), short-acting (regular human insulin), intermediate-acting (NPH), long-acting (e.g., insulin glargine U100/U300, detemir, degludec), and ultra-long-acting (e.g., insulin glargine U300, degludec). Basal insulins provide background glucose control, while prandial (mealtime) insulins address postprandial excursions. For many people with type 1 diabetes, a basal–bolus regimen combining a long-acting basal insulin with rapid-acting bolus insulin at meals offers optimal flexibility and glycemic control. In type 2 diabetes, insulin initiation often begins with once-daily basal insulin (e.g., glargine or degludec), titrated to achieve fasting glucose targets, with bolus insulin added only if needed. Newer analogs like insulin degludec offer flatter pharmacokinetic profiles and lower hypoglycemia risk—particularly nocturnal—compared with older insulins, but they do not universally outperform others in every clinical scenario. Clinical decision-making should always integrate evidence-based guidelines (e.g., ADA, EASD), shared decision-making with the patient, and ongoing reassessment of safety, efficacy, and quality of life.